Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (301)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02678975 | Disulfiram in Recurrent Glioblastoma | completed | Phase 2 / Phase 3 | 88 | Sahlgrenska University HospitalOTHER | 2 | Mar 18, 2021 | clinicaltrials |
| NCT01180816 | Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA | completed | Phase 1 | 21 | Northwell HealthOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) Infection |
| completed |
| N/A |
| 42 |
| Karolinska InstitutetOTHER |
| 1 |
| Mar 1, 2021 |
| clinicaltrials |
| NCT01290939 | Bevacizumab and Lomustine for Recurrent GBM | completed | Phase 3 | 592 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 15, 2021 | clinicaltrials |
| NCT03615404 | Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma(ATTAC-P) | completed | Phase 1 | 11 | Gary Archer Ph.D.OTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT03033524 | Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma | completed | Phase 2 | 12 | PharmAbcineINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
| NCT01740258 | Bevacizumab Beyond Progression (BBP)(BBP) | completed | Phase 2 | 68 | Duke UniversityOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02209948 | Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma. | completed | Phase 2 | 166 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT02337491 | Pembrolizumab +/- Bevacizumab for Recurrent GBM | completed | Phase 2 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT02605746 | Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis | completed | Early Phase 1 | 10 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Dec 11, 2020 | clinicaltrials |
| NCT01905228 | A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm | completed | Phase 1 | 83 | IncuronINDUSTRY | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02207010 | A Phase 0 Study of AZD1775 in Recurrent GBM Patients | completed | Early Phase 1 | 20 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT01473901 | A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 | 38 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 9, 2020 | clinicaltrials |
| NCT01934361 | Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 35 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT03603379 | Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas(GBM-LIPO) | completed | Phase 1 | 9 | University Hospital, Basel, SwitzerlandOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT00031083 | Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas | completed | Phase 1 | 12 | BiogenINDUSTRY | 1 | Nov 17, 2020 | clinicaltrials |
| NCT03619239 | Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma(GBM) | completed | Phase 1 | 15 | Genexine, Inc.INDUSTRY | 1 | Nov 10, 2020 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT00586508 | Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | completed | Phase 2 | 81 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT00050986 | Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 55 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2020 | clinicaltrials |
| NCT01987830 | Bevacizumab w / Temozolomide PET & Vascular MRI For GBM | completed | N/A | 13 | Massachusetts General HospitalOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT02590263 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | completed | Phase 1 / Phase 2 | 53 | AbbVieINDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT00402116 | Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients | completed | Phase 1 / Phase 2 | 72 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 6, 2020 | clinicaltrials |
| NCT00179803 | Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors | completed | Phase 2 | 24 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT01813877 | Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma | completed | N/A | 37 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02626364 | Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification | completed | Phase 2 | 11 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT03687099 | Immunological and Functional Characterization of Cellular Population CD45+ Infiltrating Human Glioblastoma(GLIOBLASTOMES) | completed | — | 20 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT01790503 | A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 65 | Daiichi SankyoINDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT01349660 | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 88 | SCRI Development Innovations, LLCOTHER | 1 | Jun 17, 2020 | clinicaltrials |
| NCT02502708 | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | completed | Phase 1 | 81 | NewLink Genetics CorporationINDUSTRY | 1 | Jun 4, 2020 | clinicaltrials |
| NCT02343406 | Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas(INTELLANCE-2) | completed | Phase 2 | 266 | AbbVieINDUSTRY | 21 | May 22, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT02799238 | Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma(ALECSAT) | completed | Phase 2 | 62 | CytoVac A/SINDUSTRY | 1 | Apr 30, 2020 | clinicaltrials |
| NCT02431572 | A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy | completed | N/A | 11 | Massachusetts General HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT01260506 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 75 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 2 | Apr 24, 2020 | clinicaltrials |
| NCT02342379 | TH-302 in Combination With Bevacizumab for Glioblastoma | completed | Phase 2 | 35 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT01165671 | Carbon Ion Radiotherapy for Primary Glioblastoma(CLEOPATRA) | completed | N/A | 100 | University Hospital HeidelbergOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02529072 | Nivolumab With DC Vaccines for Recurrent Brain Tumors(AVERT) | completed | Phase 1 | 6 | Gary Archer Ph.D.OTHER | 1 | Mar 26, 2020 | clinicaltrials |
| NCT01067469 | Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | completed | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT01967810 | ANG1005 in Patients With Recurrent High-Grade Glioma | completed | Phase 2 | 73 | Angiochem IncINDUSTRY | 1 | Feb 25, 2020 | clinicaltrials |
| NCT01402063 | PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation | completed | Phase 2 | 63 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01498328 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma(ReACT) | completed | Phase 2 | 127 | Celldex TherapeuticsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02378532 | The Addition of Chloroquine to Chemoradiation for Glioblastoma(CHLOROBRAIN) | completed | Phase 1 | 13 | Maastricht Radiation OncologyOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT00390299 | Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01468324 | AZD7451 for Recurrent Gliomas | completed | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00009035 | Natural History of Patients With Brain and Spinal Cord Tumors | completed | — | 3,050 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01316809 | AZD8055 for Adults With Recurrent Gliomas | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01975701 | A Phase 2 Study of BGJ398 in Patients With Recurrent GBM | completed | Phase 2 | 26 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 4, 2019 | clinicaltrials |
| NCT01540513 | PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404 | completed | N/A | 12 | University of Wisconsin, MadisonOTHER | 1 | Dec 2, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2021source: clinicaltrials